AMYLIN AGONIST COMPOUNDS FOR ESTROGEN-DEFICIENT MAMMALS
Provided herein are methods to treat estrogen deficiency in mammals by administering amylin agonist compounds. Also provided herein are methods to treat obesity and overweight in estrogen-deficient mammals; methods to reduce or maintain body weight and/or body fat in estrogen-deficient mammals; and methods to increase Bdnf levels in mammals by administering effective amounts of amylin agonist compounds. The estrogen deficiency may be caused by menopause, perimenopause, post-menopause, ovarian dysfunction, an overectomy, a hysterectomy, and the like. The amylin agonist compounds may be any known in the art or described herein, such as pramlintide, davalintide, or SEQ ID NO: 142.
1 - 99 . (canceled)
100 . A method for treating estrogen deficiency in a mammal in need thereof comprising administering to the estrogen-deficient mammal a therapeutically effective amount of an amylin agonist compound.
101 . The method of claim 100 , wherein the amylin agonist compound is a compound of Formula (I), (II), (III), (IV), (VI), (VI), (VII), (VIII), (IX), or (X).
102 . The method of claim 100 , wherein the amylin agonist compound comprises the amino acid sequence of any one of SEQ ID NOs:1-139 or a pharmaceutically acceptable salt thereof
103 . The method of claim 100 , wherein the amylin agonist compound is linked to a peptide, a carbohydrate, a saccharide, a polyethylene glycol, albumin, a fatty acid, or a polyamino acid.
104 . The method of claim 100 , wherein the amylin agonist compound is pramlintide.
105 . The method of claim 100 , further comprising administering an effective amount of leptin or a leptin analog.
106 . A method for treating obesity or overweight in an estrogen-deficient mammal comprising administering to the estrogen-deficient mammal a therapeutically effective amount of an amylin agonist compound to treat the obesity or overweight in the mammal.
107 . The method of claim 106 , wherein the amylin agonist compound is a compound of Formula (I), (II), (III), (IV), (VI), (VI), (VII), (VIII), (IX), or (X).
108 . The method of claim 106 , wherein the amylin agonist compound comprises the amino acid sequence of any one of SEQ ID NOs:1-139 or a pharmaceutically acceptable salt thereof
109 . The method of claim 106 , wherein the amylin agonist compound is pramlintide.
110 . The method of claim 106 , wherein the amylin agonist compound is linked to a peptide, carbohydrate, a saccharide, a polyethylene glycol, albumin, a fatty acid, or a polyamino acid.
111 . The method of claim 106 , further comprising administering an effective amount of leptin or a leptin analog.
112 . A method for reducing weight in an estrogen-deficient mammal comprising administering to the estrogen-deficient mammal a therapeutically effective amount of an amylin agonist compound.
113 . The method of claim 112 , wherein the amylin agonist compound is a compound of Formula (I), (II), (III), (IV), (VI), (VI), (VII), (VIII), (IX), or (X).
114 . The method of claim 112 , wherein the amylin agonist compound comprises the amino acid sequence of any one of SEQ ID NOs:1-139 or a pharmaceutically acceptable salt thereof.
115 . The method of claim 112 , wherein the amylin agonist compound is pramlintide.
116 . The method of claim 112 , wherein the amylin agonist compound is linked to a peptide, a carbohydrate, a saccharide, a polyethylene glycol, albumin, a fatty acid, or a polyamino acid.
117 . A method of increasing Bdnf levels in a mammal in need thereof comprising administering to the mammal a therapeutically effective amount of an amylin agonist compound to increase Bdnf levels in the mammal.
118 . The method of claim 117 , wherein the amylin agonist compound is a compound of Formula (I), (II), (III), (IV), (VI), (VI), (VII), (VIII), (IX), or (X).
119 . The method of claim 117 , wherein the amylin agonist compound is pramlintide.